AERI Aerie Pharmaceuticals Inc.

29.53
-0.67  -2%
Previous Close 30.2
Open 30.23
Price To Book 7.07
Market Cap 1,355,953,638
Shares 45,917,834
Volume 545,613
Short Ratio
Av. Daily Volume 576,879

NewsSee all news

  1. Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
  2. Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy?
  3. See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
  4. Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT
  5. Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced March 12, 2019.
Roclatan
Glaucoma
PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
Rhopressa
Glaucoma
Phase 1/2 trial to be initiated 2Q 2019.
AR-13503
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Phase 2 trial initiated March 2019.
AR-1105
Macular edema due to RVO (retinal vein occlusion)

Latest News

  1. Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
  2. Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy?
  3. See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
  4. Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT
  5. Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting
  6. Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences
  7. Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price?
  8. Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?
  9. Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
  10. Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
  11. Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates
  12. Aerie Pharmaceuticals, Inc. (AERI) Q1 2019 Earnings Call Transcript
  13. Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates
  14. Aerie: 1Q Earnings Snapshot
  15. Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
  16. Another $100 million 'safety net' set for this Triangle pharma
  17. Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M